Zacks Research Comments on Haemonetics Co.’s Q1 2025 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for Haemonetics in a research report issued on Friday, April 19th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $0.95 per share for the quarter, up from their previous forecast of $0.94. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.05 EPS, FY2025 earnings at $4.16 EPS, Q1 2026 earnings at $1.23 EPS, Q2 2026 earnings at $1.17 EPS and FY2026 earnings at $4.85 EPS.

HAE has been the subject of several other reports. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Finally, Barrington Research reissued an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th.

Haemonetics Trading Down 2.7 %

Shares of NYSE HAE opened at $81.24 on Monday. The business has a fifty day simple moving average of $78.97 and a 200-day simple moving average of $82.67. The company has a market cap of $4.13 billion, a price-to-earnings ratio of 33.02, a P/E/G ratio of 1.92 and a beta of 0.36. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. Haemonetics has a 12 month low of $70.74 and a 12 month high of $95.26.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. During the same period in the prior year, the business posted $0.85 earnings per share. Haemonetics’s revenue was up 10.1% compared to the same quarter last year.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the business. State of Michigan Retirement System increased its position in Haemonetics by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier’s stock worth $1,065,000 after purchasing an additional 300 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Haemonetics by 132.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock worth $42,930,000 after purchasing an additional 286,897 shares during the last quarter. AlphaMark Advisors LLC acquired a new position in Haemonetics in the 1st quarter worth about $304,000. Cardinal Capital Management increased its position in Haemonetics by 26.5% in the 1st quarter. Cardinal Capital Management now owns 14,283 shares of the medical instruments supplier’s stock worth $1,219,000 after purchasing an additional 2,994 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC increased its position in Haemonetics by 2.1% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier’s stock worth $1,562,000 after purchasing an additional 374 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.